Journal Information
Vol. 88. Issue 4.
Pages 431-432 (October - December 2023)
Share
Share
Download PDF
More article options
Visits
2425
Vol. 88. Issue 4.
Pages 431-432 (October - December 2023)
Scientific letter
Full text access
Ustekinumab and remission in perianal Crohn's disease: A case report
Ustekinumab y remisión en enfermedad de Crohn con compromiso perianal: reporte de un caso
Visits
2425
C.E. Alcántara-Figueroaa,
Corresponding author
christian378@hotmail.com

Corresponding author at: Calle Los Manzanos Mz G Lote 5 A, Dpto 602, Urb. El Golf, distrito Víctor Larco Herrera, Trujillo, La Libertad, Peru. Tel.: +51969672075.
, E.F. Coronado-Riveraa, E.F. Estela-Vásquezb, D.C. Calderón-Cabreraa, R.A. Alcántara-Ascóna
a Escuela de Medicina, Universidad Privada Antenor Orrego, Trujillo, La Libertad, Peru
b Servicio de Gastroenterología, Hospital Belén, Trujillo, La Libertad, Peru
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

Crohn’s disease (CD) is a chronic inflammatory disease, characterized by periods of activity and remission, many cases of which require personalized treatment.1

A 34-year-old woman had an 8-year history of CD. She initially presented with a moderate bout of the disease, with ileocolonic involvement and anal fissures (Fig. 1a and b). Induction therapy was infliximab 5 mg/kg IV at weeks 0, 2, and 6, followed by 5 mg/kg IV infusion every 8 weeks as maintenance therapy. The patient was in clinical and endoscopic remission for one year, after which she presented with numerous bouts of mild disease, characterized by deep anal fissures that remitted with prednisone 1 mg/kg/d VO, but became corticoid dependent. She then presented with a left-sided perianal abscess and 2 complex perianal fistulas that were treated with ciprofloxacin 500 mg every 12 h and metronidazole 500 mg every 8 h for 3 months, along with setons for 8 months, curing said complications (Fig. 1c and d). The patient continued to present with several mild bouts of anal fissures that improved with prednisone 1 mg/kg/d, but they were corticoid dependent. Infliximab dose was increased to 10 mg/kg IV every 4 weeks, combined with azathioprine 2 mg/kg/d. At one year there was no clinical improvement, and so anti-infliximab antibodies and serum infliximab levels were measured (0.1 AU/mL and 17.74 µg/mL, respectively) and the patient was considered to have secondary failure. Medication was switched to ustekinumab 390 mg IV and then 90 mg SC every 8 weeks, achieving clinical and endoscopic remission at 6 months. The patient remains in remission at the follow-up visit at 2 years.

Figure 1.

a) Deep ulcer in the terminal ileum at disease onset. b) Deep anal fissures. c) Magnetic resonance imaging showing perianal abscess. d) Resolved abscess.

(0.39MB).

Anti-tumor necrosis factor agents provide significant and lasting remission in CD. However, 30% of patients do not respond to induction therapy and another 30% lose response during the first year of treatment, leading to the recommendation of switching biologics to agents, such as ustekinumab,2 which inhibits interleukin 12 and interleukin 23 in the inflammatory pathway.3 Perianal CD is a therapeutic challenge with high failure rates. Recent studies support the superior effectiveness of ustekinumab, compared with other biologic treatments.4–6 Importantly, all the studies reported that ustekinumab safely maintained clinical response and remission in patients with CD. Likewise, short-term and long-term treatments were beneficial in patients with refractory disease, avoiding invasive procedures (surgical therapy).7,8

In conclusion, ustekinumab has been shown to be a good option for achieving remission in both bio-naïve and bio-failure patients, as occurred in our patient presenting with a complex case of perianal CD.

Ethical considerations

The authors declare that no experiments were conducted on humans or animals for the present study, that they have followed the protocols of their work center on the publication of patient data, and that they have preserved patient anonymity at all times (thus informed consent was not requested). This study meets the current bioethical research norms.

Financial disclosure

No financial support was received in relation to this article.

Conflict of interest

The authors declare that there is no conflict of interest.

References
[1]
G.M. Godoy-Brewer, G. Salem, M.A. Afzal, et al.
Ustekinumab is effective for perianal fistulising Crohn’s disease: a real-world experience and systematic review with meta-analysis.
BMJ Open Gastroenterol, 8 (2021),
[2]
J.E. Paredes-Méndez, P.A. Alosilla-Sandoval, H.T. Vargas-Marcacuzco, et al.
Pérdida de respuesta a terapia anti-TNF en enfermedad inflamatoria intestinal: experiencia en un hospital de referencia en Lima — Perú.
Rev Gastroenterol Peru, 40 (2020), pp. 22-28
[3]
J.P. Gisbert, M. Chaparro.
Ustekinumab en el tratamiento de la enfermedad de Crohn.
Gastroenterol Hepatol, 40 (2017), pp. 688-698
[4]
V.B.C. Biemans, C.J. van der Woude, G. Dijkstra, et al.
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment.
Aliment Pharmacol Ther, 52 (2020), pp. 123-134
[5]
P. Rutgeerts, C. Gasink, D. Chan, et al.
Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn’s disease.
Gastroenterology, 155 (2018), pp. 1045-1058
[6]
W.J. Sandborn, R. Rebuck, Y. Wang, et al.
Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI trial.
Clin Gastroenterol Hepatol, 20 (2022),
[7]
M. Attauabi, J. Burisch, J.B. Seidelin.
Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature.
Scand J Gastroenterol, 56 (2021), pp. 53-58
[8]
C. Chapuis-Biron, J. Kirchgesner, B. Pariente, et al.
Ustekinumab for perianal Crohn’s disease: the BioLAP multicenter study from the GETAID.
Am J Gastroenterol, 115 (2020), pp. 1812-1820

Please cite this article as: Alcántara-Figueroa CE, Coronado-Rivera EF, Estela-Vásquez EF, Calderón-Cabrera DC, Alcántara-Ascón RA. Ustekinumab y remisión en enfermedad de Crohn con compromiso perianal: reporte de un caso. Rev Gastroenterol Mex. 2023;88:431–432.

Copyright © 2023. Asociación Mexicana de Gastroenterología
Idiomas
Revista de Gastroenterología de México
Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.